<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04826536</url>
  </required_header>
  <id_info>
    <org_study_id>IM011-166</org_study_id>
    <nct_id>NCT04826536</nct_id>
  </id_info>
  <brief_title>A Study of Treatment Patterns and Clinical Outcomes of Psoriasis in Japan</brief_title>
  <official_title>Treatment Patterns and Outcomes Study for Psoriasis (PSO) in Japan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to understand current real-world treatment patterns and clinical&#xD;
      outcomes, reasons for switching treatment, and participant characteristics using each&#xD;
      systemic psoriasis treatment in Japan.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 17, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Distribution of participant background at first visit: Age</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of participant background at first visit: Sex</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of participant background at first visit: Duration with psoriasis</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of participant background at first visit: Comorbidities</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of participant background at first visit: Current status of phototherapy</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment patterns: Drug names treated during study period</measure>
    <time_frame>Up to 4 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment patterns: Drug categories treated during study period</measure>
    <time_frame>Up to 4 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment patterns: Number of treatment changes during study period</measure>
    <time_frame>Up to 4 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment patterns: Treatment duration of each drug during study period</measure>
    <time_frame>Up to 4 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment patterns: Duration between withdrawal of one drug and start of a new drug during study period</measure>
    <time_frame>Up to 4 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment patterns: Adverse event (AE) at time of withdrawal of some drug</measure>
    <time_frame>Up to 4 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment patterns: Psoriasis area severity index (PASI) at time of withdrawal</measure>
    <time_frame>Up to 4 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment patterns: PASI at time of start of a new drug</measure>
    <time_frame>Up to 4 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment patterns: PASI improvement from start of one drug to withdrawal of other drug</measure>
    <time_frame>Up to 4 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment patterns: Reason for treatment change during study period</measure>
    <time_frame>Up to 4 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment patterns: Status of phototherapy combination with systemic treatment</measure>
    <time_frame>Up to 4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Distribution of comorbidities that affect treatment choice and change</measure>
    <time_frame>Up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of AEs that affect treatment choice and change</measure>
    <time_frame>Up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean number of drug changes until participants achieve PASI 75 during study period</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>75% reduction in the Psoriasis Area and Severity Index score (PASI 75)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean number of drug changes until participants achieve PASI 90 during study period</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>90% reduction in the Psoriasis Area and Severity Index score (PASI 90)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean number of drug changes until participants achieve PASI 100 during study period</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>100% reduction in the Psoriasis Area and Severity Index score (PASI 100)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total period until participants achieve PASI 75 during study period</measure>
    <time_frame>Up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total period until participants achieve PASI 90 during study period</measure>
    <time_frame>Up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total period until participants achieve PASI 100 during study period</measure>
    <time_frame>Up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean period of participants achieve PASI 75 by each systemic treatment</measure>
    <time_frame>Up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean period of participants achieve PASI 90 by each systemic treatment</measure>
    <time_frame>Up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean period of participants achieve PASI 100 by each systemic treatment</measure>
    <time_frame>Up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of relationship between the reasons for treatment change and period of withdrawal</measure>
    <time_frame>Up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy after re-start treatment measured by PASI</measure>
    <time_frame>Up to 4 years</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">120</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <description>Participants with psoriasis</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        120 participants, from 2 to 4 institutes which have a central role of psoriasis therapy in&#xD;
        Japan, will be entered into the study if they started systemic treatment after 01/01/2017&#xD;
        and followed until either 12/31/2020, death, or lost to follow-up, whichever occurs first.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of psoriasis&#xD;
&#xD;
          -  Can be followed for at least 2 years&#xD;
&#xD;
          -  Treated with any of the following systemic therapy for psoriasis at time of follow-up&#xD;
             start: Tumor Necrosis Factor (TNF) inhibitors (infliximab, adalimumab, and&#xD;
             certolizumab pegol), Interleukin (IL)-12/23 inhibitors (ustekinumab), IL-23&#xD;
             inhibitors(guselkumab, risankizumab, and tildrakizumab), IL-17 inhibitors&#xD;
             (secukinumab, ixekizumab, and brodalumab), Apremilast, Methotrexate, Cyclosporine,&#xD;
             Etretinate&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Enrolled in any clinical trials for psoriasis in their follow-up period&#xD;
&#xD;
          -  Developed psoriatic arthritis, guttate psoriasis, erythrodermic psoriasis, and&#xD;
             pustular psoriasis at time of start date&#xD;
&#xD;
          -  Treated with any of the following systemic therapy before they were diagnosed with&#xD;
             psoriasis: TNF inhibitors (infliximab, adalimumab, and certolizumab pegol), IL-12/23&#xD;
             inhibitors (ustekinumab), IL-23 inhibitors(guselkumab, risankizumab, and&#xD;
             tildrakizumab), IL-17 inhibitors (secukinumab, ixekizumab, and brodalumab),&#xD;
             Apremilast, Methotrexate, Cyclosporine, Etretinate&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Minato-ku</city>
        <state>Tokyo</state>
        <zip>1070052</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 31, 2021</study_first_submitted>
  <study_first_submitted_qc>March 31, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2021</study_first_posted>
  <last_update_submitted>March 31, 2021</last_update_submitted>
  <last_update_submitted_qc>March 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Japan</keyword>
  <keyword>Observational</keyword>
  <keyword>Psoriasis</keyword>
  <keyword>Retrospective</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

